Provectus Board decides not to execute reverse stock split in 2022; plans to seek approval again in 2023

PROVECTUS BIOPHARMACEUTICALS, INC.

Board decided not to undertake the reverse stock split and authorized share reduction approved at 2022 Annual Meeting.
Decision based on prospective factors and potential negative capital markets behavior, per Chair Ed Pershing.
Board expects to seek same stockholder approval again in 2023 at a special or annual meeting.
Provectus trades on OTCQB under ticker PVCT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.